<DOC>
	<DOCNO>NCT01513668</DOCNO>
	<brief_summary>The purpose study compare single-dose oral bioavailability acetaminophen 650 mg extend release geltabs ( contain acetaminophen 650 mg ) OHM Laboratories , USA ( subsidiary Ranbaxy ) Tylenol extend release geltabs ( contain acetaminophen 650 mg ) Mc Neil , Consumer &amp; Specialty Pharmaceuticals , U.S.A healthy , adult , male human subject feed condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Acetaminophen Extended Release Gel Tabs 650 mg Under Fed Condition</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single dose , crossover bioavailability study compare acetaminophen 650 mg extend release gel tab ( contain acetaminophen 650 mg ) OHM Laboratories ( subsidiary Ranbaxy ) Tylenol 8 Hour 650 mg extend release gel tab ( contain acetaminophen 650 mg ) Mc Neil , Consumer &amp; Specialty Pharmaceuticals healthy , adult , human , male subject feed condition . The treatment assign study subject accord SAS generate randomization schedule . Each subject receive single oral dose either Test Reference product period 240ml water ambient temperature , 30 minute start high-fat high calorie breakfast period study supervision train medical officer . During course study , safety parameter include vital sign , physical examination , medical history , clinical laboratory safety test ( haematology , biochemical parameter ) assess clinical laboratory safety test ( hematology &amp; biochemical parameter ) perform end study .</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Aged 1845 year . Had nonvegetarian diet . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . Had history hypersensitivity acetaminophen component formulation . Had evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Had presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Had presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Were positive urinary screen test drug abuse ( opiates cannabinoids ) . Had presence value , significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Had clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Had clinically abnormal ECG Chest Xray . Had history serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological hematological disease , diabetes glaucoma ( rise pressure inside eye lead blurring loss vision ) . Had history psychiatric illness , may impair ability provide write informed consent . Were regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . Had history drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Had use enzyme modify drug within 30 day prior Day 1 study . Had participate clinical trial within 12 week precede Day 1 study . Subjects , completion study , donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>